Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.

Neubauer BL, Merriman RL, Best KL, Goode RL, Sarosdy MF, Tanzer LR, Howbert JJ.

J Urol. 1992 Feb;147(2):500-4.

PMID:
1732631
[PubMed - indexed for MEDLINE]
2.

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.

Neubauer BL, Best KL, Counts DF, Goode RL, Hoover DM, Jones CD, Sarosdy MF, Shaar CJ, Tanzer LR, Merriman RL.

Prostate. 1995 Oct;27(4):220-9.

PMID:
7479389
[PubMed - indexed for MEDLINE]
3.

Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.

Neubauer BL, Best KL, Goode RL, Heiman ML, Hoover DM, Robertson DW, Sarosdy MF, Shaar CJ, Tanzer LR, Merriman RL.

Cancer Res. 1992 Sep 1;52(17):4663-71.

PMID:
1511432
[PubMed - indexed for MEDLINE]
Free Article
4.

The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.

Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR.

Cancer Res. 2003 Sep 15;63(18):6056-62.

PMID:
14522935
[PubMed - indexed for MEDLINE]
Free Article
5.

Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.

Neubauer BL, Bemis KG, Best KL, Goode RL, Merriman RL, Smith GF, Tanzer LR, Hoover DM.

Prostate. 1986;8(3):265-76.

PMID:
3703746
[PubMed - indexed for MEDLINE]
6.

Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.

Neubauer BL, Bemis KG, Best KL, Goode RL, Hoover DM, Smith GF, Tanzer LR, Merriman RL.

J Urol. 1986 Jan;135(1):163-6.

PMID:
3941458
[PubMed - indexed for MEDLINE]
7.

Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.

Desai D, Sinha I, Null K, Wolter W, Suckow MA, King T, Amin S, Sinha R.

Int J Cancer. 2010 Jul 1;127(1):230-8. doi: 10.1002/ijc.25033.

PMID:
19918950
[PubMed - indexed for MEDLINE]
8.

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.

Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS.

Urology. 1997 Dec;50(6):999-1006.

PMID:
9426741
[PubMed - indexed for MEDLINE]
9.

In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.

Sarosdy MF, Higdon AL, Demoor CA.

J Urol. 1996 Jun;155(6):2085-9.

PMID:
8618341
[PubMed - indexed for MEDLINE]
10.

Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.

Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM.

Cancer Chemother Pharmacol. 2001 Oct;48(4):319-26.

PMID:
11710633
[PubMed - indexed for MEDLINE]
11.

Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.

Oades GM, Dredge K, Kirby RS, Colston KW.

BJU Int. 2002 Oct;90(6):607-16.

PMID:
12230626
[PubMed - indexed for MEDLINE]
12.

The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.

Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT.

Cancer Res. 1992 Jun 1;52(11):3022-8.

PMID:
1591718
[PubMed - indexed for MEDLINE]
Free Article
13.

An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.

Naik HR, Lehr JE, Pienta KJ.

Anticancer Res. 1994 Nov-Dec;14(6B):2617-9.

PMID:
7872690
[PubMed - indexed for MEDLINE]
14.

Oral bropirimine immunotherapy of rodent prostate cancer.

Sarosdy MF.

Eur Urol. 1997;31 Suppl 1:5-9.

PMID:
9076480
[PubMed - indexed for MEDLINE]
15.

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8.

PMID:
10090302
[PubMed - indexed for MEDLINE]
Free Article
16.

Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.

Cadieux PA, Mikolajczak SA, Reeves J, Strathdee C, Reid G, Panchal CJ, Clarke MW.

Cancer Invest. 2006 Apr-May;24(3):246-55.

PMID:
16809150
[PubMed - indexed for MEDLINE]
17.

Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.

Heinrich JE, Pollard M, Wolter WA, Liang Z, Song H, Rosen ED, Suckow MA.

Cancer Immunol Immunother. 2007 May;56(5):725-30. Epub 2006 Sep 5.

PMID:
16953436
[PubMed - indexed for MEDLINE]
18.

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.

Cancer Res. 1999 May 15;59(10):2395-401.

PMID:
10344749
[PubMed - indexed for MEDLINE]
Free Article
19.

Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo.

Zagaja GP, Shrivastav M, Fleig MJ, Marton LJ, Rinker-Schaeffer CW, Dolan ME.

Cancer Chemother Pharmacol. 1998;41(6):505-12.

PMID:
9554596
[PubMed - indexed for MEDLINE]
20.

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):926-34.

PMID:
17363487
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk